Перейти к основному содержанию
AkademIndex

Продукты

Для разработчиков

AkademBaseОткрытый API экосистемы
Статья

STRUGGLE FOR. Italian-Polish-Spanish-Uzbek-Vietnamese Expert Forum Position Paper 2023 for better control of classical modifiable risk factors in clinical practice

Krzysztof J. Filipiak‬Department of Hypertensiology, Angiology and Internal Medicine, Poznan University of Medical Sciences, Poznan, PolandVivencio BarriosCardiology Department, University Hospital Ramon y Cajal, Alcalá University, Madrid, SpainClaudio FerriUniversity of L'Aquila, MeSVA Department, UOC Internal Medicine and Nephrology, Hypertension and Cardiovascular Prevention Unit, San Salvatore Hospital, Coppito, AQ, ItalyKhurshid FozilovSantiago J. Freire CastroServicio de Medicina Interna Complexo, Hospitalario Universitario A Coruña, SpainAgnieszka KuziorFrancisco Javier Martínez-MartínEndocrinology and Nutrition Department at Hospital Universitario de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, SpainGuzal MullabaevaLan Hieu NguyenCardiology Department, Hanoi Medical University Hospital, Hanoi, VietnamUlugbek NizamovAnna Tomaszuk−KazberukDepartment of Cardiology, Lipidology and Internal Medicine with Intensive Cardiac Care Unit, Medical University of Bialystok, PolandРаиса ТригуловаDepartment of Ischemic Heart Disease and Atherosclerosis, Republican Specialised Center of Cardiology, Tashkent, UzbekistanAleksandra Gąsecka1st Chair and Department of Cardiology, Medical University of Warsaw, Poland. [email protected]
Cardiology Journaljournal2023en
ABI

Аннотация

The progress in pharmacotherapy that has been made in recent years, including the introduction of very effective and safe lipid-lowering and antihypertensive drugs, has not yet translated into the expected universal control of blood pressure, lipid disorders and diabetes. In the STRUGGLE FOR Italian- -Polish-Spanish-Uzbek-Vietnamese Expert Forum Position Paper 2023, experts from five countries recounted several points about the paradigms of cardiological and cardiometabolic care for better control of classical modifiable risk factors in the year 2023. It is believed herein, that the need to intensify treatment, actively search for patients with cardiovascular risk factors, especially with arterial hypertension, hypercholesterolemia and diabetes, should go hand in hand with the implementation of the latest therapy, based on single pill combinations including proven, effective antihypertensive, lipid-lowering and antidiabetic molecules, many of which are listed in the present document. There is a need to use both new technological concepts, completely new drugs, as well as novel treatment concepts such as metabolic treatment in coronary artery disease, try to intensify the fight against smoking in every way, including the available range of drugs and procedures reducing the harm. This approach will provide substantially better control of the underlying cardiovascular risk factors in countries as varied as Italy, Poland, Spain, Uzbekistan and Vietnam.

Перевод пока недоступен

Темы

Идентификаторы

Цитирования и источники

Цитирований: 0Использованных источников: 0